Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients

NCT03715023 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Practical issues that could not be resolved resulting in recruitment difficulties at sites.

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: PC786
DRUG: Placebo
DRUG: SOC

Sponsor

Pulmocide Ltd